220162-64-1 Usage
Uses
Used in Pharmaceutical Industry:
Methyl 2-fluoro-4-(trifluoromethyl)benzoate is used as an intermediate for the synthesis of various organic compounds in the pharmaceutical industry. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, methyl 2-fluoro-4-(trifluoromethyl)benzoate is also utilized as an intermediate for the synthesis of various organic compounds. This contributes to the development of new agrochemical products for agricultural and pest control purposes.
Used in Organic Electronics:
Methyl 2-fluoro-4-(trifluoromethyl)benzoate is used as a building block in the creation of new materials, with potential applications in the field of organic electronics. Its unique properties make it a valuable component in the development of advanced electronic devices and materials.
Used in Material Science:
Methyl 2-fluoro-4-(trifluoromethyl)benzoate has potential applications in material science, where it can be used to develop new materials with specific properties. Its fluoro-substituted aromatic structure contributes to the creation of innovative materials for various industries.
It is important to handle methyl 2-fluoro-4-(trifluoromethyl)benzoate with care, as it may pose health and environmental risks. Proper safety measures should be taken during its production, use, and disposal to minimize any potential hazards.
Check Digit Verification of cas no
The CAS Registry Mumber 220162-64-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,2,0,1,6 and 2 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 220162-64:
(8*2)+(7*2)+(6*0)+(5*1)+(4*6)+(3*2)+(2*6)+(1*4)=81
81 % 10 = 1
So 220162-64-1 is a valid CAS Registry Number.
220162-64-1Relevant articles and documents
TrkA Inhibitor
-
Paragraph 0038; 0039, (2021/12/03)
The present invention relates to compound of the following structure for use as an inhibitor of TrkA, as well as compositions including this compound, and methods of using this compound for the treatment of pain including post-surgical pain, rheumatoid arthritis pain, neuropathic pain and osteoarthritis pain.
SAR Studies on Aromatic Acylhydrazone-Based Inhibitors of Fungal Sphingolipid Synthesis as Next-Generation Antifungal Agents
Del Poeta, Maurizio,Haranahalli, Krupanandan,Lazzarini, Cristina,Mallamo, John,McCarthy, J. Brian,Ojima, Iwao,Pathiranage, Senuri,Sun, Yi,Zambito, Julia
, (2019/09/06)
Recently, the fungal sphingolipid glucosylceramide (GlcCer) synthesis has emerged as a highly promising new target for drug discovery of next-generation antifungal agents, and we found two aromatic acylhydrazones as effective inhibitors of GlcCer synthesis based on HTP screening. In the present work, we have designed libraries of new aromatic acylhydrazones, evaluated their antifungal activities (MIC80 and time-kill profile) against C. neoformans, and performed an extensive SAR study, which led to the identification of five promising lead compounds, exhibiting excellent fungicidal activities with very large selectivity index. Moreover, two compounds demonstrated broad spectrum antifungal activity against six other clinically relevant fungal strains. These five lead compounds were examined for their synergism/cooperativity with five clinical drugs against seven fungal strains, and very encouraging results were obtained; e.g., the combination of all five lead compounds with voriconazole exhibited either synergistic or additive effect to all seven fungal strains.
